A case of a Metastatic Gastric Cancer successfully treated with checkpoint inhibitors
DISCLOSURE OF INTEREST

No conflicts of interest
History and Diagnosis

✔ MIKE: male, 64 y.o, ECOG PS 0

✔ No previous medical conditions

✔ Family history of cancer: negative

✔ T/A CT SCAN:

August 2018
Treatment

1° Line: XELOX → Best Response (BR): PD (August – November 2018)

2° Line: Paclitaxel + Ramucirumab → BR: lymph node and peritoneal PD (December 2018 – February 2019)

Clear evidence of a chemo-resistant disease

Is this patient lost or not?
A deeper molecular assessment..

**FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication**

- **MMR deficient genes (by IHC)**
  - Loss of expression of $MLH1$ and $PMS2$

- **High degree of Microsatellite instability (by PCR)**

**Treatment and results**

**February 2019**

- **Pembrolizumab**
- **CEA**: 21.7 ug/L
- **CA 19.9**: not expressed

**May 2019**

- **CEA**: 14.8 ug/L

**August 2019**

- **CEA**: 7 ug/L
- **No toxicities from the treatment have been reported**
- **Significant improvement**  Patient Performance Status (ECOG PS 0)
Thanks for your attention!